therapeutic aspects [ftcn]
Hormone replacement therapy [topp]
postmenopausal [tmco]
Women [popg]
Metabolic syndrome [dsyn]
Cardiologist [prog]
opinion [menp]
Study [mnob]
effects [qlco]
Hormone replacement therapy [topp]
H+ [elii]
Metabolic Profile [npop]
Insulin Resistance [patf]
Central [spco]
Peripheral [spco]
Hemodynamics [ortf]
Endothelial [tisu]
function [phsf]
antioxidant activity [moft]
postmenopausal [tmco]
Women [popg]
Metabolic syndrome [dsyn]
Material [sbst]
Methods [inpr]
Study [mnob]
included [ftcn]
postmenopausal [tmco]
Women [popg]
Metabolic syndrome [dsyn]
Receive [qlco]
Angeliq [horm, phsu, strd]
Medication [phsu]
Estradiol 1 MG [clnd]
drospirenone 2 MG [clnd]
months [tmco]
baseline [bodm]
months [tmco]
Start [tmco]
treatment [ftcn]
Fasting [fndg]
Hour [tmco]
Postprandial [tmco]
Levels [qlco]
Lipids [lipd]
Glucose [bacs, carb, phsu]
Insulin [aapp, horm, phsu]
Measured [qlco]
Parameters [fndg]
included [ftcn]
IR [geoa]
Index [inpr]
Body Composition [orga]
Visceral Fat [tisu]
Percentage [qnco]
24 hour blood pressure [orgf]
Monitoring [hlca]
Echocardiography [diap]
Microcirculation [ortf]
Parameters [fndg]
endothelial dysfunction [dsyn]
Oxidative Stress [comd]
Marker [clna]
Body Mass Index [diap]
Decreased [qnco]
kg-m [qnco]
kg-m [qnco]
P NOS [aapp, imft]
Visceral Fat [tisu]
Percentage [qnco]
Changed [ftcn]
baseline [bodm]
months [tmco]
P NOS [aapp, imft]
natural menopause [orgf]
Course [tmco]
progressing [ftcn]
IR [geoa]
Menopausal syndrome [dsyn]
Metabolic [ftcn]
Reduced [qlco]
24 hour blood pressure [orgf]
Monitoring [hlca]
participants [popg]
Target [ftcn]
Left ventricular mass [fndg]
Myocardial [spco]
Index [inpr]
Decreased [qnco]
P NOS [aapp, imft]
Levels [qlco]
Left Ventricular Function [ortf]
Diastolic [clna]
Improved [qlco]
treatment [ftcn]
CORRECTION [inpr]
Pathological [bmod]
Microcirculation [ortf]
Types [qlco]
Maximal [qlco]
Improvement [cnce]
Observed [ftcn]
Spastic [sosy]
Microcirculation [ortf]
superoxide dismutase activity [moft]
Increased [qnco]
P NOS [aapp, imft]
Point [qnco]
Anti-Oxidant Effects [phsf]
Medication [phsu]
Angeliq [horm, phsu, strd]
therapy [ftcn]
effective [qlco]
female patients [orga]
High Risk [qlco]
CARDIOVASCULAR [bdsy]
Negative [qlco]
Metabolic Profile [npop]
IR [geoa]
Observed [ftcn]
therapy [ftcn]
Microcirculation [ortf]
Improvement [cnce]
reduction [npop]
Medication [phsu]
antioxidant activity [moft]
